TWI302459B - - Google Patents

Download PDF

Info

Publication number
TWI302459B
TWI302459B TW091118723A TW91118723A TWI302459B TW I302459 B TWI302459 B TW I302459B TW 091118723 A TW091118723 A TW 091118723A TW 91118723 A TW91118723 A TW 91118723A TW I302459 B TWI302459 B TW I302459B
Authority
TW
Taiwan
Prior art keywords
lipid
composition
drug
encapsulated
fatty acid
Prior art date
Application number
TW091118723A
Other languages
English (en)
Chinese (zh)
Inventor
T Sung Michael
Original Assignee
T Sung Michael
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by T Sung Michael filed Critical T Sung Michael
Application granted granted Critical
Publication of TWI302459B publication Critical patent/TWI302459B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW091118723A 2001-08-23 2002-08-19 TWI302459B (https=)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31409201P 2001-08-23 2001-08-23
US10/134,329 US7125568B2 (en) 2001-08-23 2002-04-29 Lipophilic drug compositions

Publications (1)

Publication Number Publication Date
TWI302459B true TWI302459B (https=) 2008-11-01

Family

ID=26832219

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091118723A TWI302459B (https=) 2001-08-23 2002-08-19

Country Status (6)

Country Link
US (2) US7125568B2 (https=)
EP (1) EP1420828B1 (https=)
CA (1) CA2458394C (https=)
ES (1) ES2395408T3 (https=)
TW (1) TWI302459B (https=)
WO (1) WO2003018064A2 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050170004A1 (en) * 2003-10-31 2005-08-04 Vered Rosenberger Nanoparticles for drug delivery
CA2604640A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories L.C. Methods for treating diseases through interruption of protein maturation, compounds that inhibit the function of molecular chaperones such as protein disulfide isomerases or interfere with glycosylation, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
AP2907A (en) 2006-01-09 2014-05-31 Romark Lab Lc Viral hepatitis treatment
US20100119529A1 (en) * 2006-05-12 2010-05-13 Furgeson Darin Y Elastin-like polymer delivery vehicles
US20100104625A1 (en) * 2007-02-16 2010-04-29 Cornell University Biodegradable compositions and materials
US8354116B2 (en) * 2007-06-18 2013-01-15 Biochemics, Inc. Bifunctional synthetic molecules
US7790401B2 (en) * 2007-08-06 2010-09-07 Siemens Healthcare Diagnostics Methods for detection of immunosuppressant drugs
TW200936180A (en) * 2007-11-27 2009-09-01 Intervet Int Bv Carrier particle for a microorganism or subunit thereof, pharmaceutical composition comprising such particles, method for preparation of this composition and its use in the treatment of animals
GB0724550D0 (en) * 2007-12-18 2008-01-30 Univ Hull Formulations
GB0812513D0 (en) * 2008-07-09 2008-08-13 Univ Hull Delivery vehicle
US20110082156A1 (en) * 2009-10-05 2011-04-07 Milne Jill C Fatty acid acipimox derivatives and their uses
CA2811931C (en) 2010-10-20 2015-06-16 Galderma S.A. Method of treating herpes virus infection using macrocyclic lactone compound
US20160289175A1 (en) * 2013-11-05 2016-10-06 Ultragenyx Pharmaceutical Inc. Creatine analogs and the use thereof
EP3475442B1 (en) 2016-06-23 2024-10-23 The Regents of The University of Michigan 12(s)-hydroxyeicosatrienoic acid compounds and their use as therapeutic agents
KR102678696B1 (ko) 2017-12-01 2024-06-27 울트라제닉스 파마수티컬 인코포레이티드 크레아틴 전구약물, 조성물과 이의 사용 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
US3931213A (en) 1974-12-18 1976-01-06 Interx Research Corporation 3-Chloro-2-oxazolidinones
DE2655369A1 (de) 1976-12-03 1978-06-08 Schering Ag 5-(subst. phenyl)-oxazolidinone und deren schwefelanaloga sowie verfahren zu deren herstellung
US4315018A (en) 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
US5340587A (en) 1985-05-22 1994-08-23 Liposome Technology, Inc. Liposome/bronchodilator method & System
DE3686025T2 (de) 1985-05-22 1993-01-07 Liposome Technology Inc Verfahren und system zum einatmen von liposomen.
JPH0751496B2 (ja) 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
EP0316594B1 (en) 1987-10-21 1993-09-29 The Du Pont Merck Pharmaceutical Company Aminomethyl oxooxazolidinyl ethenylbenzene derivatives useful as antibacterial agents
US5994392A (en) 1988-02-26 1999-11-30 Neuromedica, Inc. Antipsychotic prodrugs comprising an antipsychotic agent coupled to an unsaturated fatty acid
WO1990003795A1 (en) 1988-10-05 1990-04-19 Vestar, Inc. Method of making liposomes with improved stability during drying
US5043165A (en) 1988-12-14 1991-08-27 Liposome Technology, Inc. Novel liposome composition for sustained release of steroidal drugs
EP0458167B1 (en) 1990-05-21 1997-04-23 Abbott Laboratories Fatty acid-pulmonary surfactant conjugates
US6147204A (en) 1990-06-11 2000-11-14 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US6060080A (en) 1990-07-16 2000-05-09 Daiichi Pharmaceutical Co., Ltd. Liposomal products
DE69211691T2 (de) 1991-04-19 1997-01-16 Nexstar Pharmaceuticals Inc., Boulder, Col. Pharmazeutische formulierung und pharmazeutisches verfahren
ATE146783T1 (de) 1991-11-01 1997-01-15 Upjohn Co Substituierte aryl- und heteroaryl- phenyloxazolidinone
SK283420B6 (sk) 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
PL174222B1 (pl) 1993-01-27 1998-06-30 Inst Farmaceutyczny Środek farmaceutyczny działający na ośrodkowy układ nerwowy
US5512671A (en) 1993-02-16 1996-04-30 Wake Forest University Ether lipid-nucleoside covalent conjugates
US5576016A (en) 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
US5688792A (en) 1994-08-16 1997-11-18 Pharmacia & Upjohn Company Substituted oxazine and thiazine oxazolidinone antimicrobials
US5668286A (en) 1994-03-15 1997-09-16 Pharmacia & Upjohn Company Oxazolidinone derivatives and pharmaceutical compositions containing them
US5534499A (en) 1994-05-19 1996-07-09 The University Of British Columbia Lipophilic drug derivatives for use in liposomes
US5599831A (en) 1994-05-27 1997-02-04 Poretz; Ronald D. Method of preparation of pharmaceutical compositions
EP0781138B1 (en) 1994-08-29 2008-05-21 Wake Forest University Lipid analogs for treating viral infections
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US5952499A (en) 1995-01-16 1999-09-14 Commonwealth Scientific And Industrial Research Organisation Therapeutic compound-fatty acid conjugates
US5907030A (en) 1995-01-25 1999-05-25 University Of Southern California Method and compositions for lipidization of hydrophilic molecules
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
RU2175324C2 (ru) 1995-09-01 2001-10-27 Фармация Энд Апджон Компани Фенилоксазолидиноны, имеющие с-с-связь с 4-8-членными гетероциклическими кольцами
ES2192221T3 (es) 1995-10-30 2003-10-01 Oleoyl Estrone Developments S Monoesteres de oleato de estrogenos para el tratamiento de la obesidad o el sobrepeso.
ZA969622B (en) 1995-12-13 1998-05-15 Upjohn Co Oxazolidinone antibacterial agents having a six-membered heteroaromatic ring.
IL117773A (en) 1996-04-02 2000-10-31 Pharmos Ltd Solid lipid compositions of coenzyme Q10 for enhanced oral bioavailability
US5997899A (en) 1996-10-01 1999-12-07 Skyepharma Inc. Method for producing liposomes with increased percent of compound encapsulated
US6071532A (en) 1996-10-15 2000-06-06 Emory University Synthesis of glycophospholipid and peptide-phospholipid conjugates and uses thereof
US5874111A (en) 1997-01-07 1999-02-23 Maitra; Amarnath Process for the preparation of highly monodispersed polymeric hydrophilic nanoparticles
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6153119A (en) 1997-05-09 2000-11-28 Sung; Michael Method and product for reducing tar and nicotine in cigarettes
CA2289702C (en) 1997-05-14 2008-02-19 Inex Pharmaceuticals Corp. High efficiency encapsulation of charged therapeutic agents in lipid vesicles
US6080725A (en) 1997-05-20 2000-06-27 Galenica Pharmaceuticals, Inc. Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
CN1305374A (zh) 1998-07-14 2001-07-25 法玛西雅厄普约翰美国公司 治疗眼部感染的噁唑烷酮
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
GB9907715D0 (en) 1999-04-01 1999-05-26 Scherer Corp R P Pharmaceutical compositions
GB9930026D0 (en) 1999-12-21 2000-02-09 Univ Sheffield Novel compounds of unsaturated fatty acids
US6288238B1 (en) 2000-09-19 2001-09-11 Board Of Trustees Operating Michigan State University Process for the preparation of 5-hydroxymethyl 2-oxazolidinone and novel intermediate
ATE556706T1 (de) 2001-03-23 2012-05-15 Luitpold Pharm Inc Fettalkohol-arzneimittel-konjugate

Also Published As

Publication number Publication date
US20030108596A1 (en) 2003-06-12
EP1420828B1 (en) 2012-09-26
US7390506B2 (en) 2008-06-24
WO2003018064A2 (en) 2003-03-06
CA2458394C (en) 2013-04-23
US20060147525A1 (en) 2006-07-06
EP1420828A2 (en) 2004-05-26
ES2395408T3 (es) 2013-02-12
WO2003018064A3 (en) 2003-09-25
US7125568B2 (en) 2006-10-24
CA2458394A1 (en) 2003-03-06

Similar Documents

Publication Publication Date Title
TWI302459B (https=)
US8426368B2 (en) Method of ameliorating oxidative stress and supplementing the diet
CN100438862C (zh) 辅酶q作为活性成分的经粘膜给药的组合物
JP2001517621A (ja) 局所用非ステロイド系抗炎症剤組成物
EP0524961B1 (fr) Derives azoiques, compositions pharmaceutiques et desinfectantes les contenant et leurs utilisations contre le sida
FR2564096A1 (fr) Derives lipophiles de muramylpeptides ayant des proprietes d'activation des macrophages, compositions les contenant et procede pour les obtenir
CN116650490B (zh) 化合物mt-1207在降低尿酸方面的应用
KR0133555B1 (ko) 5-플루오로우라실계 화합물에 기인한 염증의 발생을 억제할 수 있는 비-주사제 형태의 항암조성물
Srivastava Pharmacology: A Book Of Achieving Knowledge For Drugs
RU2738658C1 (ru) Лекарственное средство в виде комплекса 3,3'-дииндолилметана и β-циклодекстрина, способ его получения и способ лечения цервикальных неоплазий с его применением
JP2003026567A (ja) 補酵素ｑを有効成分とする粘膜投与用組成物
AU2002329796B2 (en) Lipophilic drug compositions
FR2569563A1 (fr) Formulation a base de benzoylecgonine ou de benzoylnorecgonine pour le traitement du rhumatisme articulaire
CN1300208A (zh) 冰淇淋型药物制剂及其制备方法
AU2002329796A1 (en) Lipophilic drug compositions
WO2001082915A2 (en) Trans-clitoral administration of therapy
JPH0383915A (ja) 経粘膜製剤
RU2541156C1 (ru) Трансдермальное антигельминтное средство на основе кремнийорганических ниосом с альбендазолом
TWI336252B (en) Pharmaceutical composition for the treatment and prevention of obesity
CN103980228B (zh) 具有快速皮肤穿透速度的带正电荷的水溶性的昔康及其相关化合物的前药
RU2007144347A (ru) Производные докозагексаеновой кислоты и их применение в качестве лекарственных средств
CN112358477A (zh) 一种用于治疗胆囊炎的药物及其制备方法
WO2020041193A1 (en) Lipofullerene conjugates and their use for promotion of hair growth and prevention of hair loss
KR910018026A (ko) α-페닐-α피리딜알칸산 유도체를 함유하는 배뇨장애증상 치료제
WO2005058878A1 (ja) 月経困難症の予防および／または治療剤